Long-acting G-CSF is standard supportive care in myelosuppressive chemotherapy, a market reshaped by pegfilgrastim biosimilars competing largely on price. Rolvedon (eflapegrastim) entered as a distinct molecule rather than a biosimilar.
Its novel Fc-linked construct stimulates the bone marrow to produce neutrophils, shortening the period of severe neutropenia. Injected once per chemotherapy cycle, it decreases infection incidence in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy that carries a clinically significant risk of febrile neutropenia.
Because it was approved as a novel biologic rather than a biosimilar, Rolvedon received its own regulatory exclusivity and a distinct reimbursement code. Whether that differentiation justifies premium pricing in a commoditized class is its defining commercial question.
